An observational, cross-sectional, longitudinal, microdosing Position Emission Tomography (PET) imaging study to investigate platelet derived growth factor receptor beta (PDGFRß) expression in the heart of patients with high or low risk of heart failure after a ST-Elevation Myocardial Infarction (STEMI) after a percutaneous coronary intervention (PCI) with a stent procedure, as well as in patients with heart failure with preserved ejection fraction (HFpEF) and healthy individuals.
Who can participate
Age range
40 Years – 70 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Willing and able to give written informed consent for participation in the trial and able to comply with all trial procedures and requirements.
* Male or female participant aged 40 to 70 years, inclusive, at the screening visit.
* Women of childbearing potential must practice abstinence from heterosexual intercourse or must agree to use a highly effective method of contraception.
Cohort-specific inclusion criteria:
Cohort 1, STEMI high-risk patients:
* NT-proBNP \>500 pg/mL within 48 hrs after PCI
* Post-PCI Thrombolysis In Myocardial Infarction (TIMI) score \<3.
* No previous history of coronary artery disease or heart failure.
Cohort 2, STEMI low-risk patients
* NT-proBNP \<500 pg/mL within 48 hrs after PCI
* Post-PCI TIMI score 3.
* No previous history of coronary artery disease or heart failure.
Cohort 3 (HFpEF patients)
* Presence of signs and symptoms of HF
* Ejection Fraction ≥50%
* Elevated levels of natriuretic peptides (NT-proBNP≥125pg/mL)
* At least one of the following:
* Relevant structural heart disease (left ventricular hypertrophy or left atrial enlargement)
* Diastolic dysfunction
Cohort 4 (healthy participants)
* Individuals with no history of coronary disease or heart failure.
* Medically healthy participant without abnormal clinically significant medical history, physical findings, vital signs, ECG, and laboratory values at the time of the screening visit, as judged by the Investigator.
Exclusion Criteria:
* Any contraindi…
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
PET-tracer binding in myocardium
Timeframe: At PET/MRI baseline, and at PET/MRI at 2-8 months after baseline (cohort 1 and 2)
2
PET-tracer binding in the infarct
Timeframe: At PET/MRI baseline, and at PET/MRI at 2-8 months after baseline (cohort 1 and 2)